Globus Medical (GMED) Financials

$70.53 +0.03 (+0.05%)

Closing price 03:59 PM Eastern

Extended Trading

$68.86 -1.67 (-2.36%)

As of 06:20 PM Eastern

Annual Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	113	104	107	156	155	102	149	190	123	103
Consolidated Net Income / (Loss)	113	104	107	156	155	102	149	190	123	103
Net Income / (Loss) Continuing Operations	113	104	107	156	155	102	149	190	123	103
Total Pre-Tax Income	173	157	170	189	190	126	180	243	165	121
Total Operating Income	172	154	162	169	172	111	172	228	133	166
Total Gross Profit	412	429	486	554	605	572	719	759	1,020	1,484
Total Revenue	545	564	636	713	785	789	958	1,023	1,568	2,519
Operating Revenue	545	564	636	713	785	789	958	1,023	1,568	2,519
Total Cost of Revenue	132	135	150	159	180	217	239	264	548	1,035
Operating Cost of Revenue	132	135	150	159	180	217	239	264	548	1,035
Total Operating Expenses	240	275	324	384	433	460	547	531	887	1,318
Selling, General & Admin Expense	210	222	268	312	355	355	408	432	643	981
Research & Development Expense	36	45	44	55	60	85	97	73	124	164
Amortization Expense	1.56	3.48	7.91	9.59	14	17	19	18	51	119
Restructuring Charge	3.35	1.83	1.61	1.68	2.58	4.03	17	5.96	68	53
Other Special Charges / (Income)	-11	3.16	2.67	5.88	2.19	0.01	5.92	2.34	0.43	0.31
Total Other Income / (Expense), net	1.17	3.14	8.09	19	18	14	8.45	15	32	-45
Interest Expense	-1.30	-3.06	-6.61	-13	-17	-14	-9.30	-14	-20	4.19
Other Income / (Expense), net	-0.14	0.08	1.48	6.00	0.55	0.51	-0.84	0.84	12	-41
Income Tax Expense	60	53	63	32	35	24	31	53	43	18
Basic Earnings per Share	$1.19	$1.09	$1.12	$1.60	$1.57	$1.04	$1.48	$1.89	$1.09	$0.76
Weighted Average Basic Shares Outstanding	95.05M	95.65M	96.24M	97.88M	99.15M	98.58M	100.73M	100.47M	113.09M	135.73M
Diluted Earnings per Share	$1.17	$1.08	$1.10	$1.54	$1.52	$1.01	$1.44	$1.85	$1.07	$0.75
Weighted Average Diluted Shares Outstanding	96.07M	96.43M	97.89M	101.32M	102.00M	100.97M	103.62M	102.64M	114.63M	137.86M
Weighted Average Basic & Diluted Shares Outstanding	94.80M	95.70M	95.80M	97.80M	99.84M	99.80M	101.56M	100.30M	135.37M	137.54M

This table shows Globus Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	47	50	49	58	1.00	15	-7.12	32	52	27
Consolidated Net Income / (Loss)	47	50	49	58	1.00	15	-7.12	32	52	27
Net Income / (Loss) Continuing Operations	47	50	49	58	1.00	15	-7.12	32	52	27
Total Pre-Tax Income	61	62	63	75	2.54	25	-8.56	48	57	25
Total Operating Income	60	54	56	66	0.40	10	8.00	50	48	60
Total Gross Profit	189	204	206	215	248	351	365	370	355	394
Total Revenue	254	274	277	292	384	617	607	630	626	657
Operating Revenue	254	274	277	292	384	617	607	630	626	657
Total Cost of Revenue	65	71	71	76	135	265	241	260	271	263
Operating Cost of Revenue	65	71	71	76	135	265	241	260	271	263
Total Operating Expenses	129	150	149	149	248	341	357	320	307	334
Selling, General & Admin Expense	107	118	122	120	156	245	249	238	241	253
Research & Development Expense	19	20	21	21	29	52	57	38	35	33
Amortization Expense	4.32	4.51	4.60	4.55	14	28	30	30	30	30
Restructuring Charge	-0.65	7.79	1.36	5.71	46	16	22	13	1.57	17
Other Special Charges / (Income)	0.00	-	0.00	-2.74	2.92	0.25	-0.03	1.34	-0.68	-0.31
Total Other Income / (Expense), net	1.76	8.39	6.79	8.46	2.13	15	-17	-2.04	8.93	-36
Interest Expense	-3.90	-5.32	-6.50	-8.29	-7.92	2.58	1.89	2.34	0.78	-0.82
Other Income / (Expense), net	-2.14	3.07	0.29	0.17	-5.79	17	-15	0.29	9.71	-36
Income Tax Expense	14	12	14	17	1.54	9.96	-1.44	16	5.20	-1.84
Basic Earnings per Share	$0.48	$0.50	$0.49	$0.57	$0.01	$0.02	($0.05)	$0.23	$0.38	$0.20
Weighted Average Basic Shares Outstanding	99.65M	100.47M	100.28M	100.37M	113.54M	113.09M	135.36M	135.20M	135.62M	135.73M
Diluted Earnings per Share	$0.47	$0.48	$0.48	$0.57	$0.01	$0.01	($0.05)	$0.23	$0.38	$0.19
Weighted Average Diluted Shares Outstanding	101.42M	102.64M	102.20M	101.78M	115.25M	114.63M	135.36M	136.98M	138.06M	137.86M
Weighted Average Basic & Diluted Shares Outstanding	99.84M	100.30M	100.33M	100.46M	137.79M	135.37M	135.06M	135.41M	136.17M	137.54M

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-25	-16	51	21	56	44	-46	-43	317	317
Net Cash From Operating Activities	124	148	159	182	172	199	276	178	243	521
Net Cash From Continuing Operating Activities	124	148	159	182	172	199	276	178	243	521
Net Income / (Loss) Continuing Operations	113	104	107	156	155	102	149	190	123	103
Consolidated Net Income / (Loss)	113	104	107	156	155	102	149	190	123	103
Depreciation Expense	24	39	42	42	53	63	70	68	145	254
Amortization Expense	3.35	4.07	2.67	1.68	-1.09	0.59	2.78	5.39	81	241
Non-Cash Adjustments To Reconcile Net Income	9.87	24	28	30	32	72	72	37	52	119
Changes in Operating Assets and Liabilities, net	-26	-23	-21	-48	-67	-39	-18	-122	-157	-197
Net Cash From Investing Activities	-153	-163	-111	-193	-140	-117	-376	-110	303	-176
Net Cash From Continuing Investing Activities	-153	-163	-111	-193	-140	-117	-376	-110	303	-176
Purchase of Property, Plant & Equipment	-51	-41	-51	-60	-71	-64	-57	-74	-78	-115
Acquisitions	-49	-76	-30	-15	-24	-33	-34	-31	-296	-18
Purchase of Investments	-300	-350	-393	-538	-347	-224	-622	-420	-101	-114
Sale and/or Maturity of Investments	246	335	363	384	301	203	338	415	778	71
Net Cash From Financing Activities	4.28	0.47	1.63	33	24	-39	54	-110	-232	-28
Net Cash From Continuing Financing Activities	4.28	0.47	1.63	33	24	-39	54	-110	-232	-28
Repurchase of Common Equity	-	-	-	0.00	0.00	-105	0.00	-144	-226	-86
Other Financing Activities, net	4.28	0.47	1.63	33	24	66	54	35	-6.26	58
Effect of Exchange Rate Changes	0.15	-1.89	1.98	-	-0.16	0.87	-0.81	-0.75	2.18	0.26
Cash Income Taxes Paid	57	50	59	31	34	25	45	78	101	159

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-17	16	67	89	-27	188	-113	56	212	162
Net Cash From Operating Activities	33	64	53	35	50	105	52	54	204	210
Net Cash From Continuing Operating Activities	33	64	53	35	50	105	52	54	204	210
Net Income / (Loss) Continuing Operations	47	50	49	58	1.00	15	-7.12	32	52	27
Consolidated Net Income / (Loss)	47	50	49	58	1.00	15	-7.12	32	52	27
Depreciation Expense	18	17	18	18	37	71	55	64	67	68
Amortization Expense	1.24	0.94	0.48	0.30	19	61	60	60	67	53
Non-Cash Adjustments To Reconcile Net Income	9.39	8.99	11	11	28	1.84	32	23	14	50
Changes in Operating Assets and Liabilities, net	-43	-13	-26	-52	-35	-44	-88	-124	3.28	12
Net Cash From Investing Activities	-63	-60	11	52	-81	321	-47	-10	-15	-104
Net Cash From Continuing Investing Activities	-63	-60	11	52	-81	321	-47	-10	-15	-104
Purchase of Property, Plant & Equipment	-12	-18	-16	-18	-22	-23	-29	-28	-42	-17
Purchase of Investments	-143	-97	-69	-12	-19	-	-8.02	-4.16	-1.19	-100
Sale and/or Maturity of Investments	92	86	99	82	253	343	2.65	26	28	13
Net Cash From Financing Activities	13	14	2.94	1.08	1.43	-237	-116	8.71	20	60
Net Cash From Continuing Financing Activities	13	14	2.94	1.08	1.43	-237	-116	8.71	20	60
Repurchase of Common Equity	-	-	0.00	-	-	-226	-83	-1.47	-	-1.00
Other Financing Activities, net	13	14	2.94	1.08	1.43	-12	-32	10	20	61
Effect of Exchange Rate Changes	0.48	-0.84	-0.03	0.43	2.12	-0.35	-3.31	3.77	4.07	-4.28
Cash Income Taxes Paid	22	20	1.72	37	26	35	1.97	70	46	41

This table presents Globus Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	834	928	1,079	1,301	1,532	1,679	1,957	2,076	5,086	5,252
Total Current Assets	545	514	620	631	687	822	865	983	1,915	2,177
Cash & Equivalents	60	67	-	-	-	-	193	150	467	784
Short-Term Investments	221	223	255	200	116	187	250	296	50	106
Accounts Receivable	78	92	117	137	154	142	164	213	503	558
Inventories, net	105	113	108	131	196	229	237	299	848	659
Prepaid Expenses	7.35	15	11	15	17	18	18	21	45	50
Current Deferred & Refundable Income Taxes	47	3.80	8.72	7.29	8.10	6.42	1.22	4.06	1.64	21
Plant, Property, & Equipment, net	115	124	143	172	200	217	221	244	587	562
Total Noncurrent Assets	175	290	315	498	645	641	872	849	2,584	2,513
Long-Term Investments	49	60	56	263	410	359	562	496	75	66
Goodwill	92	106	124	124	129	157	180	197	1,435	1,432
Intangible Assets	33	62	79	87	79	87	69	64	925	795
Noncurrent Deferred & Refundable Income Taxes	0.00	31	20	14	5.93	6.62	24	49	11	94
Other Noncurrent Operating Assets	0.59	0.93	7.95	10	22	32	36	43	139	125
Total Liabilities & Shareholders' Equity	834	928	1,079	1,301	1,532	1,679	1,957	2,076	5,086	5,252
Total Liabilities	119	96	111	115	130	173	216	230	1,088	1,074
Total Current Liabilities	83	80	93	96	111	121	140	159	392	856
Short-Term Debt	-	-	-	-	-	-	-	-	0.00	443
Accounts Payable	16	17	25	26	25	18	22	36	57	75
Accrued Expenses	54	46	53	60	63	78	91	92	240	261
Current Deferred Revenue	-	0.00	0.76	2.60	5.40	8.13	12	14	18	22
Current Deferred & Payable Income Tax Liabilities	0.76	1.91	3.27	0.92	1.06	1.10	1.05	0.99	3.85	11
Other Current Liabilities	12	14	11	6.83	17	15	14	16	73	44
Total Noncurrent Liabilities	36	16	18	19	18	52	76	71	696	219
Long-Term Debt	-	-	-	-	-	-	-	0.00	417	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	13	7.88	11	8.11	6.02	6.20	4.31	1.78	84	24
Other Noncurrent Operating Liabilities	23	7.79	6.98	11	12	46	71	69	194	195
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177
Total Preferred & Common Equity	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177
Total Common Equity	715	832	968	1,186	1,402	1,506	1,741	1,846	3,998	4,177
Common Stock	193	212	238	300	357	457	554	631	2,871	3,031
Retained Earnings	525	629	736	893	1,048	1,045	1,194	1,240	1,137	1,153
Accumulated Other Comprehensive Income / (Loss)	-1.96	-8.64	-6.91	-7.17	-2.90	3.96	-6.77	-25	-10	-6.86

This table presents Globus Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,977	2,150	2,212	5,356	4,944	4,994	5,086
Total Current Assets	920	1,070	1,210	1,917	1,829	1,924	2,057
Cash & Equivalents	134	218	306	280	354	410	623
Short-Term Investments	271	287	306	189	80	83	72
Accounts Receivable	206	223	240	494	534	612	588
Inventories, net	282	321	336	905	816	770	718
Prepaid Expenses	24	19	20	48	43	46	51
Current Deferred & Refundable Income Taxes	2.20	3.04	1.76	1.74	0.37	2.50	5.15
Plant, Property, & Equipment, net	236	245	248	607	579	572	568
Total Noncurrent Assets	820	834	754	2,832	2,536	2,498	2,462
Long-Term Investments	504	480	392	276	51	28	12
Goodwill	182	199	199	1,122	1,451	1,454	1,432
Intangible Assets	54	59	55	1,262	888	867	843
Noncurrent Deferred & Refundable Income Taxes	45	51	62	7.32	11	18	45
Other Noncurrent Operating Assets	36	45	47	164	135	131	129
Total Liabilities & Shareholders' Equity	1,977	2,150	2,212	5,356	4,944	4,994	5,086
Total Liabilities	212	235	227	1,169	1,021	1,017	1,017
Total Current Liabilities	145	168	155	429	786	794	818
Short-Term Debt	-	-	-	-	424	430	437
Accounts Payable	32	40	34	87	50	67	58
Accrued Expenses	88	84	90	222	210	216	255
Current Deferred Revenue	12	14	15	18	17	20	21
Current Deferred & Payable Income Tax Liabilities	1.31	16	1.76	34	43	11	4.17
Other Current Liabilities	11	14	15	68	42	49	43
Total Noncurrent Liabilities	67	67	72	740	235	223	199
Long-Term Debt	-	-	-	410	0.00	0.00	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	1.58	1.37	5.30	132	40	27	7.48
Other Noncurrent Operating Liabilities	66	66	67	198	195	196	191
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,764	1,915	1,985	4,187	3,922	3,976	4,069
Total Preferred & Common Equity	1,764	1,915	1,985	4,187	3,922	3,976	4,069
Total Common Equity	1,764	1,915	1,985	4,187	3,922	3,976	4,069
Common Stock	606	645	657	2,858	2,887	2,914	2,950
Retained Earnings	1,190	1,289	1,347	1,348	1,047	1,074	1,126
Accumulated Other Comprehensive Income / (Loss)	-32	-19	-19	-19	-11	-12	-6.96

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.84%	3.53%	12.76%	12.11%	10.15%	0.47%	21.43%	6.76%	53.34%	60.62%
EBITDA Growth	22.74%	-1.23%	5.58%	5.08%	2.54%	-21.76%	38.97%	24.07%	22.55%	67.38%
EBIT Growth	24.59%	-10.38%	5.90%	7.35%	-1.59%	-35.12%	52.85%	33.71%	-36.51%	-14.01%
NOPAT Growth	21.78%	-9.02%	-0.02%	37.40%	0.04%	-35.58%	57.07%	25.44%	-44.55%	43.16%
Net Income Growth	21.95%	-7.49%	2.88%	45.76%	-0.81%	-34.10%	45.86%	27.47%	-35.39%	-16.19%
EPS Growth	20.62%	-7.69%	1.85%	40.00%	-1.30%	-33.55%	42.57%	28.47%	-42.16%	-29.91%
Operating Cash Flow Growth	56.63%	19.21%	7.60%	14.20%	-5.32%	15.59%	38.98%	-35.40%	36.44%	113.82%
Free Cash Flow Firm Growth	-64.64%	-273.93%	335.48%	111.98%	-56.32%	21.89%	150.77%	-92.66%	-30,147.99%	110.62%
Invested Capital Growth	39.29%	33.79%	11.87%	8.32%	16.94%	5.81%	2.00%	22.98%	322.59%	-4.12%
Revenue Q/Q Growth	2.60%	1.62%	4.00%	2.87%	2.04%	2.84%	1.76%	2.45%	27.89%	1.64%
EBITDA Q/Q Growth	9.84%	-4.96%	1.91%	-0.99%	4.03%	7.86%	-14.40%	14.90%	29.58%	-2.21%
EBIT Q/Q Growth	10.79%	-12.03%	8.96%	-2.92%	3.94%	9.24%	-19.55%	20.68%	-16.89%	-2.90%
NOPAT Q/Q Growth	9.45%	-11.77%	-0.47%	7.07%	6.35%	9.64%	-20.23%	20.08%	-28.35%	61.69%
Net Income Q/Q Growth	9.69%	-11.31%	0.07%	8.59%	6.00%	7.83%	-20.24%	22.52%	-22.18%	12.53%
EPS Q/Q Growth	8.33%	-10.74%	0.00%	7.69%	4.83%	10.99%	-20.88%	21.71%	-30.52%	31.58%
Operating Cash Flow Q/Q Growth	55.35%	-11.81%	13.16%	-0.30%	6.19%	14.96%	-1.40%	-6.44%	20.07%	25.46%
Free Cash Flow Firm Q/Q Growth	129.26%	16.51%	-11.95%	35.90%	-16.74%	59.00%	-27.80%	-65.20%	1.41%	113.52%
Invested Capital Q/Q Growth	3.16%	-1.32%	-0.15%	-2.80%	0.00%	-1.50%	0.30%	5.80%	-0.78%	-3.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.71%	76.12%	76.34%	77.64%	77.08%	72.44%	75.03%	74.22%	65.05%	58.90%
EBITDA Margin	36.63%	34.94%	32.71%	30.67%	28.55%	22.23%	25.44%	29.57%	23.63%	24.62%
Operating Margin	31.61%	27.33%	25.45%	23.75%	21.90%	14.12%	17.95%	22.29%	8.49%	6.59%
EBIT Margin	31.59%	27.34%	25.68%	24.59%	21.97%	14.19%	17.86%	22.37%	9.26%	4.96%
Profit (Net Income) Margin	20.70%	18.50%	16.88%	21.95%	19.76%	12.96%	15.57%	18.59%	7.83%	4.09%
Tax Burden Percent	65.27%	66.34%	63.17%	82.96%	81.71%	81.24%	82.70%	78.25%	74.29%	85.31%
Interest Burden Percent	100.42%	101.98%	104.05%	107.57%	110.09%	112.46%	105.43%	106.22%	113.86%	96.65%
Effective Tax Rate	34.73%	33.66%	36.83%	17.04%	18.29%	18.76%	17.30%	21.75%	25.71%	14.69%
Return on Invested Capital (ROIC)	36.41%	24.34%	20.07%	25.07%	22.23%	12.91%	19.53%	21.75%	4.19%	3.78%
ROIC Less NNEP Spread (ROIC-NNEP)	36.30%	23.75%	18.76%	21.97%	20.02%	11.35%	18.75%	20.54%	-0.10%	15.00%
Return on Net Nonoperating Assets (RNNOA)	-19.07%	-10.85%	-8.14%	-10.54%	-10.24%	-5.88%	-10.34%	-11.15%	0.02%	-1.26%
Return on Equity (ROE)	17.34%	13.49%	11.93%	14.53%	11.99%	7.03%	9.19%	10.60%	4.20%	2.52%
Cash Return on Invested Capital (CROIC)	3.57%	-4.56%	8.86%	17.08%	6.61%	7.27%	17.54%	1.14%	-119.27%	7.99%
Operating Return on Assets (OROA)	22.38%	17.51%	16.28%	14.74%	12.18%	6.97%	9.41%	11.34%	4.06%	2.42%
Return on Assets (ROA)	14.67%	11.85%	10.70%	13.15%	10.96%	6.37%	8.20%	9.43%	3.43%	1.99%
Return on Common Equity (ROCE)	17.34%	13.48%	11.93%	14.53%	11.99%	7.03%	9.19%	10.60%	4.20%	2.52%
Return on Equity Simple (ROE_SIMPLE)	15.77%	12.54%	11.09%	13.20%	11.07%	6.79%	8.57%	10.30%	3.07%	2.47%
Net Operating Profit after Tax (NOPAT)	112	102	102	140	141	91	142	178	99	142
NOPAT Margin	20.63%	18.13%	16.08%	19.70%	17.89%	11.47%	14.84%	17.44%	6.31%	5.62%
Net Nonoperating Expense Percent (NNEP)	0.11%	0.59%	1.31%	3.10%	2.22%	1.56%	0.78%	1.21%	4.29%	-11.22%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	9.66%	2.24%	3.06%
Cost of Revenue to Revenue	24.29%	23.88%	23.66%	22.36%	22.92%	27.56%	24.97%	25.78%	34.95%	41.10%
SG&A Expenses to Revenue	38.59%	39.39%	42.11%	43.70%	45.17%	44.96%	42.60%	42.25%	41.02%	38.94%
R&D to Revenue	6.67%	7.90%	6.87%	7.78%	7.65%	10.71%	10.16%	7.14%	7.91%	6.50%
Operating Expenses to Revenue	44.09%	48.79%	50.90%	53.89%	55.18%	58.32%	57.08%	51.93%	56.56%	52.31%
Earnings before Interest and Taxes (EBIT)	172	154	163	175	173	112	171	229	145	125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	200	197	208	219	224	175	244	302	371	620
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.70	2.86	4.09	3.60	4.17	4.27	4.21	4.02	1.84	2.70
Price to Tangible Book Value (P/TBV)	4.49	3.58	5.18	4.37	4.90	5.10	4.91	4.68	4.48	5.78
Price to Revenue (P/Rev)	4.86	4.22	6.23	5.98	7.45	8.16	7.65	7.25	4.68	4.47
Price to Earnings (P/E)	23.49	22.79	36.90	27.24	37.71	62.92	49.11	38.99	59.76	109.36
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.26%	4.39%	2.71%	3.67%	2.65%	1.59%	2.04%	2.56%	1.67%	0.91%
Enterprise Value to Invested Capital (EV/IC)	6.38	4.21	6.56	6.28	7.53	7.84	8.59	7.16	1.88	2.93
Enterprise Value to Revenue (EV/Rev)	4.21	3.59	5.55	5.13	6.53	7.16	6.60	6.33	4.57	4.27
Enterprise Value to EBITDA (EV/EBITDA)	11.50	10.28	16.97	16.74	22.89	32.21	25.93	21.40	19.34	17.33
Enterprise Value to EBIT (EV/EBIT)	13.33	13.14	21.62	20.87	29.75	50.47	36.94	28.29	49.34	86.06
Enterprise Value to NOPAT (EV/NOPAT)	20.40	19.81	34.54	26.05	36.52	62.41	44.45	36.29	72.46	75.91
Enterprise Value to Operating Cash Flow (EV/OCF)	18.50	13.71	22.20	20.15	29.84	28.42	22.88	36.27	29.43	20.65
Enterprise Value to Free Cash Flow (EV/FCFF)	208.08	0.00	78.22	38.24	122.78	110.90	49.47	690.06	0.00	35.92
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.11
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00
Financial Leverage	-0.53	-0.46	-0.43	-0.48	-0.51	-0.52	-0.55	-0.54	-0.19	-0.08
Leverage Ratio	1.18	1.14	1.11	1.10	1.09	1.10	1.12	1.12	1.23	1.26
Compound Leverage Factor	1.19	1.16	1.16	1.19	1.21	1.24	1.18	1.19	1.40	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.45%	9.59%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.59%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.45%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.99%	99.99%	99.99%	100.00%	100.00%	99.99%	100.00%	100.00%	90.55%	90.41%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.71
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.47	-0.83
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.13	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	3.13
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.78	-3.62
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.22	0.00
Altman Z-Score	16.26	17.59	24.10	24.66	29.39	24.36	22.44	21.53	5.12	7.46
Noncontrolling Interest Sharing Ratio	0.01%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.59	6.43	6.67	6.56	6.17	6.80	6.17	6.18	4.88	2.54
Quick Ratio	4.34	4.79	4.01	3.51	2.42	2.72	4.34	4.14	2.60	1.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	-19	45	96	42	51	128	9.38	-2,819	299
Operating Cash Flow to CapEx	244.30%	361.35%	310.04%	332.09%	243.07%	312.28%	485.56%	241.02%	311.09%	451.05%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	71.44
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	124.29
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	96.73
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.71	0.64	0.63	0.60	0.55	0.49	0.53	0.51	0.44	0.49
Accounts Receivable Turnover	7.12	6.65	6.10	5.62	5.39	5.33	6.26	5.42	4.38	4.75
Inventory Turnover	1.35	1.24	1.36	1.33	1.10	1.02	1.03	0.98	0.96	1.37
Fixed Asset Turnover	5.91	4.72	4.76	4.53	4.23	3.79	4.38	4.40	3.78	4.39
Accounts Payable Turnover	7.11	8.06	7.08	6.26	7.13	10.16	11.91	9.09	11.82	15.71
Days Sales Outstanding (DSO)	51.29	54.90	59.88	64.95	67.71	68.46	58.31	67.39	83.37	76.85
Days Inventory Outstanding (DIO)	270.59	295.28	268.20	274.38	332.16	357.06	355.62	370.90	381.90	265.67
Days Payable Outstanding (DPO)	51.35	45.31	51.57	58.31	51.22	35.93	30.64	40.18	30.89	23.23
Cash Conversion Cycle (CCC)	270.53	304.88	276.51	281.02	348.66	389.59	383.29	398.12	434.38	319.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	359	481	538	583	681	721	735	904	3,822	3,664
Invested Capital Turnover	1.76	1.34	1.25	1.27	1.24	1.13	1.32	1.25	0.66	0.67
Increase / (Decrease) in Invested Capital	101	121	57	45	99	40	14	169	2,918	-158
Enterprise Value (EV)	2,294	2,026	3,531	3,659	5,132	5,650	6,320	6,473	7,167	10,750
Market Capitalization	2,649	2,377	3,961	4,262	5,853	6,436	7,326	7,415	7,343	11,262
Book Value per Share	$7.51	$8.68	$10.04	$12.04	$14.11	$15.26	$17.16	$18.49	$29.01	$30.68
Tangible Book Value per Share	$6.20	$6.93	$7.94	$9.89	$12.02	$12.79	$14.71	$15.88	$11.89	$14.32
Total Capital	715	832	968	1,186	1,402	1,506	1,741	1,846	4,415	4,621
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	417	443
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	417	0.00
Net Debt	-356	-351	-430	-603	-721	-785	-1,006	-942	-176	-513
Capital Expenditures (CapEx)	51	41	51	55	71	64	57	74	78	115
Debt-free, Cash-free Net Working Capital (DFCFNWC)	155	143	154	195	265	274	281	378	1,005	875
Debt-free Net Working Capital (DFNWC)	462	434	527	535	576	701	724	824	1,523	1,765
Net Working Capital (NWC)	462	434	527	535	576	701	724	824	1,523	1,321
Net Nonoperating Expense (NNE)	-0.38	-2.08	-5.11	-16	-15	-12	-6.99	-12	-24	39
Net Nonoperating Obligations (NNO)	-356	-351	-430	-603	-721	-785	-1,006	-942	-176	-513
Total Depreciation and Amortization (D&A)	27	43	45	43	52	63	73	74	225	495
Debt-free, Cash-free Net Working Capital to Revenue	28.45%	25.37%	24.15%	27.33%	33.69%	34.76%	29.32%	36.96%	64.09%	34.72%
Debt-free Net Working Capital to Revenue	84.83%	76.93%	82.91%	74.98%	73.35%	88.84%	75.60%	80.57%	97.10%	70.05%
Net Working Capital to Revenue	84.83%	76.93%	82.91%	74.98%	73.35%	88.84%	75.60%	80.57%	97.10%	52.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.19	$1.09	$1.12	$1.60	$1.57	$1.04	$1.48	$1.89	$1.09	$0.76
Adjusted Weighted Average Basic Shares Outstanding	95.05M	95.65M	96.24M	97.88M	99.15M	98.58M	100.73M	100.47M	113.09M	135.73M
Adjusted Diluted Earnings per Share	$1.17	$1.08	$1.10	$1.54	$1.52	$1.01	$1.44	$1.85	$1.07	$0.75
Adjusted Weighted Average Diluted Shares Outstanding	96.07M	96.43M	97.89M	101.32M	102.00M	100.97M	103.62M	102.64M	114.63M	137.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	95.37M	95.97M	96.73M	98.65M	99.84M	99.80M	101.56M	100.30M	135.37M	137.54M
Normalized Net Operating Profit after Tax (NOPAT)	107	106	105	147	144	94	161	185	150	187
Normalized NOPAT Margin	19.69%	18.72%	16.50%	20.58%	18.39%	11.89%	16.82%	18.07%	9.56%	7.44%
Pre Tax Income Margin	31.72%	27.89%	26.72%	26.45%	24.19%	15.96%	18.83%	23.76%	10.54%	4.79%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.82
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	33.80
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.26
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.25
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	102.33%	0.00%	75.98%	183.57%	83.30%

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.63%	9.79%	20.01%	10.61%	50.95%	124.60%	119.26%	115.93%	63.10%	6.61%
EBITDA Growth	9.54%	109.75%	16.57%	-2.02%	-33.21%	112.89%	44.72%	105.04%	276.51%	-8.79%
EBIT Growth	9.97%	219.20%	23.10%	-2.47%	-109.35%	-51.71%	-111.75%	-24.80%	1,173.48%	-13.50%
NOPAT Growth	-0.36%	214.05%	21.23%	-2.44%	-99.65%	-86.02%	-87.23%	-35.27%	27,385.65%	963.68%
Net Income Growth	0.47%	231.42%	29.00%	5.72%	-97.90%	-69.97%	-114.49%	-44.97%	5,093.99%	76.30%
EPS Growth	4.44%	220.00%	29.73%	7.55%	-97.87%	-97.92%	-110.42%	-59.65%	3,700.00%	1,800.00%
Operating Cash Flow Growth	-57.39%	-16.10%	19.30%	-5.03%	53.35%	63.62%	-1.74%	54.90%	303.40%	100.95%
Free Cash Flow Firm Growth	-268.00%	-22,053.07%	-2,618.06%	-181.37%	-3,868.12%	-2,220.88%	-2,309.60%	-2,461.71%	103.21%	107.64%
Invested Capital Growth	16.58%	22.98%	21.59%	19.98%	350.61%	322.59%	314.94%	296.25%	-1.37%	-4.12%
Revenue Q/Q Growth	-3.60%	8.01%	0.80%	5.39%	31.56%	60.71%	-1.60%	3.80%	-0.63%	5.05%
EBITDA Q/Q Growth	-11.71%	-1.87%	0.44%	12.59%	-39.82%	212.80%	-31.72%	59.52%	10.51%	-24.22%
EBIT Q/Q Growth	-15.42%	-0.81%	-0.72%	17.09%	-108.11%	612.09%	-124.17%	849.04%	15.81%	-58.74%
NOPAT Q/Q Growth	-12.16%	-5.48%	0.71%	16.69%	-99.69%	3,728.22%	-8.06%	491.69%	31.98%	48.15%
Net Income Q/Q Growth	-13.11%	5.55%	-1.87%	17.47%	-98.27%	1,406.41%	-147.34%	546.26%	63.21%	-48.87%
EPS Q/Q Growth	-11.32%	2.13%	0.00%	18.75%	-98.25%	0.00%	-600.00%	560.00%	65.22%	-50.00%
Operating Cash Flow Q/Q Growth	-10.74%	94.33%	-16.67%	-34.30%	44.12%	107.34%	-49.95%	3.57%	275.34%	3.28%
Free Cash Flow Firm Q/Q Growth	-89.54%	-66.10%	3.25%	7.62%	-2,573.02%	2.85%	-0.45%	1.79%	103.35%	130.97%
Invested Capital Q/Q Growth	4.58%	5.80%	2.87%	5.41%	292.79%	-0.78%	1.01%	0.66%	-2.23%	-3.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.23%	74.28%	74.40%	73.78%	64.71%	56.94%	60.19%	58.70%	56.77%	59.92%
EBITDA Margin	30.05%	27.31%	27.21%	29.07%	13.30%	25.88%	17.96%	27.60%	30.70%	22.14%
Operating Margin	23.49%	19.68%	20.39%	22.71%	0.11%	1.64%	1.32%	7.88%	7.69%	9.17%
EBIT Margin	22.65%	20.80%	20.49%	22.76%	-1.40%	4.47%	-1.10%	7.93%	9.24%	3.63%
Profit (Net Income) Margin	18.66%	18.24%	17.76%	19.79%	0.26%	2.44%	-1.17%	5.04%	8.28%	4.03%
Tax Burden Percent	77.17%	80.60%	77.75%	77.29%	39.37%	60.15%	83.16%	66.75%	90.89%	107.45%
Interest Burden Percent	106.77%	108.78%	111.46%	112.49%	-47.08%	90.64%	128.42%	95.32%	98.66%	103.42%
Effective Tax Rate	22.83%	19.40%	22.25%	22.71%	60.63%	39.85%	0.00%	33.25%	9.11%	-7.45%
Return on Invested Capital (ROIC)	22.79%	19.79%	19.98%	21.41%	0.02%	0.66%	0.73%	4.83%	4.53%	6.63%
ROIC Less NNEP Spread (ROIC-NNEP)	22.65%	19.12%	19.46%	20.72%	-0.11%	-0.95%	3.16%	5.08%	1.84%	17.74%
Return on Net Nonoperating Assets (RNNOA)	-12.32%	-10.38%	-10.54%	-10.61%	0.02%	0.18%	-0.57%	-0.93%	-0.14%	-1.49%
Return on Equity (ROE)	10.47%	9.41%	9.44%	10.80%	0.05%	0.84%	0.16%	3.90%	4.39%	5.14%
Cash Return on Invested Capital (CROIC)	3.39%	1.14%	2.46%	2.38%	-121.49%	-119.27%	-119.80%	-117.68%	3.66%	7.99%
Operating Return on Assets (OROA)	11.64%	10.55%	10.56%	12.10%	-0.47%	1.96%	-0.59%	4.92%	4.39%	1.77%
Return on Assets (ROA)	9.59%	9.25%	9.15%	10.52%	0.09%	1.07%	-0.63%	3.13%	3.93%	1.97%
Return on Common Equity (ROCE)	10.47%	9.41%	9.44%	10.80%	0.05%	0.84%	0.16%	3.90%	4.39%	5.14%
Return on Equity Simple (ROE_SIMPLE)	8.80%	0.00%	10.51%	10.29%	3.77%	0.00%	1.70%	1.02%	2.25%	0.00%
Net Operating Profit after Tax (NOPAT)	46	44	44	51	0.16	6.09	5.60	33	44	65
NOPAT Margin	18.13%	15.86%	15.85%	17.55%	0.04%	0.99%	0.92%	5.26%	6.99%	9.85%
Net Nonoperating Expense Percent (NNEP)	0.14%	0.67%	0.53%	0.69%	0.13%	1.60%	-2.43%	-0.25%	2.68%	-11.11%
Return On Investment Capital (ROIC_SIMPLE)	-	2.36%	-	-	-	0.14%	-	-	-	1.40%
Cost of Revenue to Revenue	25.77%	25.72%	25.60%	26.22%	35.29%	43.06%	39.81%	41.30%	43.23%	40.08%
SG&A Expenses to Revenue	41.93%	43.01%	44.24%	41.17%	40.72%	39.69%	41.00%	37.82%	38.47%	38.56%
R&D to Revenue	7.36%	7.11%	7.62%	7.32%	7.64%	8.48%	9.44%	5.99%	5.65%	5.08%
Operating Expenses to Revenue	50.74%	54.60%	54.02%	51.07%	64.60%	55.30%	58.88%	50.82%	49.08%	50.75%
Earnings before Interest and Taxes (EBIT)	58	57	57	66	-5.39	28	-6.66	50	58	24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	76	75	75	85	51	160	109	174	192	146
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.36	4.02	2.97	3.01	1.19	1.84	1.88	2.33	2.38	2.70
Price to Tangible Book Value (P/TBV)	3.88	4.68	3.43	3.45	2.77	4.48	4.67	5.59	5.40	5.78
Price to Revenue (P/Rev)	5.94	7.25	5.31	5.45	4.07	4.68	3.89	4.14	3.91	4.47
Price to Earnings (P/E)	38.19	38.99	28.23	29.24	31.59	59.76	110.93	227.41	105.85	109.36
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.62%	2.56%	3.54%	3.42%	3.17%	1.67%	0.90%	0.44%	0.94%	0.91%
Enterprise Value to Invested Capital (EV/IC)	5.87	7.16	5.05	5.07	1.21	1.88	1.90	2.36	2.48	2.93
Enterprise Value to Revenue (EV/Rev)	5.03	6.33	4.39	4.53	3.79	4.57	3.86	4.10	3.80	4.27
Enterprise Value to EBITDA (EV/EBITDA)	19.07	21.40	15.00	15.96	16.27	19.34	18.13	18.57	14.84	17.33
Enterprise Value to EBIT (EV/EBIT)	26.47	28.29	19.62	20.90	26.62	49.34	89.49	139.97	73.21	86.06
Enterprise Value to NOPAT (EV/NOPAT)	33.78	36.29	25.25	26.90	33.70	72.46	121.58	219.93	107.53	75.91
Enterprise Value to Operating Cash Flow (EV/OCF)	26.31	36.27	25.10	26.83	22.94	29.43	30.22	34.99	22.69	20.65
Enterprise Value to Free Cash Flow (EV/FCFF)	186.19	690.06	225.65	231.97	0.00	0.00	0.00	0.00	67.19	35.92
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.10	0.10	0.11	0.11	0.11	0.11
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.10	0.10	0.00	0.00	0.00	0.00
Financial Leverage	-0.54	-0.54	-0.54	-0.51	-0.21	-0.19	-0.18	-0.18	-0.07	-0.08
Leverage Ratio	1.12	1.12	1.12	1.12	1.23	1.23	1.22	1.21	1.26	1.26
Compound Leverage Factor	1.19	1.22	1.25	1.26	-0.58	1.11	1.56	1.15	1.25	1.31
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	8.91%	9.45%	9.76%	9.77%	9.70%	9.59%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.76%	9.77%	9.70%	9.59%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	8.91%	9.45%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	91.09%	90.55%	90.24%	90.23%	90.30%	90.41%
Debt to EBITDA	0.00	0.00	0.00	0.00	1.43	1.13	1.05	0.87	0.69	0.71
Net Debt to EBITDA	0.00	0.00	0.00	0.00	-1.17	-0.47	-0.15	-0.18	-0.43	-0.83
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	1.43	1.13	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	2.97	4.22	7.03	10.34	4.99	3.13
Net Debt to NOPAT	0.00	0.00	0.00	0.00	-2.43	-1.78	-1.02	-2.17	-3.08	-3.62
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	2.97	4.22	0.00	0.00	0.00	0.00
Altman Z-Score	18.66	21.26	16.45	17.78	3.47	5.05	5.27	6.51	6.84	7.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.33	6.18	6.39	7.80	4.47	4.88	2.33	2.42	2.51	2.54
Quick Ratio	4.21	4.14	4.34	5.50	2.25	2.60	1.23	1.39	1.57	1.69
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-76	-125	-121	-112	-2,997	-2,912	-2,925	-2,872	96	222
Operating Cash Flow to CapEx	274.72%	348.83%	333.39%	196.04%	234.44%	457.47%	183.38%	195.19%	485.45%	1,229.26%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-1,128.09	-1,544.17	-1,230.10	124.25	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	40.56	27.66	23.24	262.78	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	31.69	12.58	11.33	208.65	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.51	0.52	0.53	0.33	0.44	0.54	0.62	0.47	0.49
Accounts Receivable Turnover	5.46	5.42	5.50	5.07	3.50	4.38	5.02	5.25	4.58	4.75
Inventory Turnover	0.99	0.98	0.96	0.94	0.60	0.96	1.26	1.63	1.28	1.37
Fixed Asset Turnover	4.42	4.40	4.52	4.51	2.91	3.78	4.61	5.46	4.22	4.39
Accounts Payable Turnover	9.68	9.09	8.35	8.33	5.94	11.82	15.92	17.87	14.36	15.71
Days Sales Outstanding (DSO)	66.88	67.39	66.41	72.04	104.23	83.37	72.78	69.52	79.68	76.85
Days Inventory Outstanding (DIO)	369.95	370.90	381.01	387.43	613.39	381.90	288.72	223.68	285.43	265.67
Days Payable Outstanding (DPO)	37.69	40.18	43.69	43.80	61.43	30.89	22.93	20.42	25.41	23.23
Cash Conversion Cycle (CCC)	399.14	398.12	403.73	415.67	656.19	434.38	338.57	272.78	339.70	319.29
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	855	904	930	981	3,852	3,822	3,861	3,886	3,800	3,664
Invested Capital Turnover	1.26	1.25	1.26	1.22	0.52	0.66	0.79	0.92	0.65	0.67
Increase / (Decrease) in Invested Capital	122	169	165	163	2,997	2,918	2,930	2,905	-53	-158
Enterprise Value (EV)	5,019	6,473	4,697	4,970	4,653	7,167	7,330	9,160	9,417	10,750
Market Capitalization	5,928	7,415	5,681	5,974	4,988	7,343	7,391	9,250	9,687	11,262
Book Value per Share	$17.73	$18.49	$19.09	$19.78	$41.68	$29.01	$28.98	$29.44	$30.05	$30.68
Tangible Book Value per Share	$15.36	$15.88	$16.52	$17.25	$17.95	$11.89	$11.70	$12.26	$13.26	$14.32
Total Capital	1,764	1,846	1,915	1,985	4,597	4,415	4,346	4,407	4,507	4,621
Total Debt	0.00	0.00	0.00	0.00	410	417	424	430	437	443
Total Long-Term Debt	0.00	0.00	0.00	0.00	410	417	0.00	0.00	0.00	0.00
Net Debt	-909	-942	-984	-1,004	-335	-176	-62	-90	-270	-513
Capital Expenditures (CapEx)	12	18	16	18	22	23	29	28	42	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	369	378	399	442	1,020	1,005	1,032	1,067	981	875
Debt-free Net Working Capital (DFNWC)	775	824	903	1,055	1,489	1,523	1,466	1,560	1,676	1,765
Net Working Capital (NWC)	775	824	903	1,055	1,489	1,523	1,042	1,130	1,238	1,321
Net Nonoperating Expense (NNE)	-1.36	-6.52	-5.28	-6.54	-0.84	-8.95	13	1.36	-8.12	38
Net Nonoperating Obligations (NNO)	-909	-942	-984	-1,004	-335	-176	-62	-90	-270	-513
Total Depreciation and Amortization (D&A)	19	18	19	18	56	132	116	124	134	122
Debt-free, Cash-free Net Working Capital to Revenue	37.01%	36.96%	37.28%	40.29%	83.14%	64.09%	54.35%	47.72%	39.57%	34.72%
Debt-free Net Working Capital to Revenue	77.60%	80.57%	84.46%	96.16%	121.38%	97.10%	77.24%	69.76%	67.60%	70.05%
Net Working Capital to Revenue	77.60%	80.57%	84.46%	96.16%	121.38%	97.10%	54.90%	50.51%	49.97%	52.45%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.48	$0.50	$0.49	$0.57	$0.01	$0.02	($0.05)	$0.23	$0.38	$0.20
Adjusted Weighted Average Basic Shares Outstanding	99.65M	100.47M	100.28M	100.37M	113.54M	113.09M	135.36M	135.20M	135.62M	135.73M
Adjusted Diluted Earnings per Share	$0.47	$0.48	$0.48	$0.57	$0.01	$0.01	($0.05)	$0.23	$0.38	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	101.42M	102.64M	102.20M	101.78M	115.25M	114.63M	135.36M	136.98M	138.06M	137.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	99.84M	100.30M	100.33M	100.46M	137.79M	135.37M	135.06M	135.41M	136.17M	137.54M
Normalized Net Operating Profit after Tax (NOPAT)	46	50	45	53	34	16	21	43	45	54
Normalized NOPAT Margin	17.93%	18.15%	16.23%	18.33%	8.93%	2.53%	3.41%	6.80%	7.12%	8.21%
Pre Tax Income Margin	24.18%	22.63%	22.84%	25.61%	0.66%	4.05%	-1.41%	7.56%	9.11%	3.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	10.68	-3.52	21.38	74.59	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	2.36	2.96	14.19	56.41	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	1.82	-18.60	9.47	20.46	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-6.51	-12.13	2.28	2.28	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	93.09%	75.98%	0.00%	0.00%	0.00%	183.57%	463.59%	763.00%	339.13%	83.30%

Frequently Asked Questions About Globus Medical's Financials

When does Globus Medical's fiscal year end?

According to the most recent income statement we have on file, Globus Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Globus Medical's net income changed over the last 9 years?

In the past 9 years, Globus Medical's net income has ranged from $102.29 million in 2020 to $190.17 million in 2022, and is currently $102.98 million as of their latest financial filing in 2024. See where experts think Globus Medical is headed by visiting Globus Medical's forecast page.

What is Globus Medical's operating income?

Globus Medical's total operating income in 2024 was $165.99 million, based on the following breakdown:

Total Gross Profit: $1.48 billion
Total Operating Expenses: $1.32 billion

How has Globus Medical revenue changed over the last 9 years?

Over the last 9 years, Globus Medical's total revenue changed from $544.75 million in 2015 to $2.52 billion in 2024, a change of 362.5%.

How much debt does Globus Medical have?

Globus Medical's total liabilities were at $1.07 billion at the end of 2024, a 1.3% decrease from 2023, and a 804.6% increase since 2015.

How much cash does Globus Medical have?

In the past 9 years, Globus Medical's cash and equivalents has ranged from $0.00 in 2017 to $784.44 million in 2024, and is currently $784.44 million as of their latest financial filing in 2024.

How has Globus Medical's book value per share changed over the last 9 years?

Over the last 9 years, Globus Medical's book value per share changed from 7.51 in 2015 to 30.68 in 2024, a change of 308.5%.

Related Companies

This page (NYSE:GMED) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Financials

Frequently Asked Questions About Globus Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Financials

Annual Income Statements for Globus Medical

Quarterly Income Statements for Globus Medical

Annual Cash Flow Statements for Globus Medical

Quarterly Cash Flow Statements for Globus Medical

Annual Balance Sheets for Globus Medical

Quarterly Balance Sheets for Globus Medical

Annual Metrics and Ratios for Globus Medical

Quarterly Metrics and Ratios for Globus Medical

Frequently Asked Questions About Globus Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools